We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
+10.46%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$235M
AUM Growth
+$15.3M
(+7%)
Cap. Flow
+$7.44M
Cap. Flow
% of AUM
3.16%
Top 10 Holdings %
Top 10 Hldgs %
31.26%
Holding
99
New
22
Increased
25
Reduced
15
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$6.47M |
| 2 |
Centene
CNC
|
+$4.68M |
| 3 |
Stryker
SYK
|
+$4.47M |
| 4 |
AET
Aetna Inc
AET
|
+$4.31M |
| 5 |
GSK
GSK
|
+$4.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$7.97M |
| 2 |
AbbVie
ABBV
|
+$5.99M |
| 3 |
Agilent Technologies
A
|
+$3.59M |
| 4 |
Pfizer
PFE
|
+$2.77M |
| 5 |
ELGX
Endologix Inc
ELGX
|
+$2.66M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 62.78% |
| 2 | Financials | 4.02% |
| 3 | Industrials | 1.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
PUT
DELISTED
Allergan plc
AGN
| $9.82M | 4.17% |
42,500
-42,500
| -50% | -$9.8M |
|
|
AET
2
DELISTED
Aetna Inc
AET
| $9.46M | 4.02% |
77,500
+37,500
| +94% | +$4.31M |
|
|
3
Centene
CNC
$30.5B
| $7.49M | 3.19% |
210,000
+148,952
| +244% | +$4.68M |
|
4
PUT
First Trust Health Care AlphaDEX Fund
FXH
$1.05B
| $7.37M | 3.13% |
125,000
+30,000
| +32% | +$1.74M |
|
|
5
Medtronic
MDT
$112B
| $6.94M | 2.95% |
+80,000
| New | +$6.47M |
|
6
Baxter International
BAX
$12.8B
| $6.66M | 2.83% |
147,305
-7,695
| -5% | -$338K |
|
7
Zimmer Biomet
ZBH
$18.8B
| $6.62M | 2.81% |
56,650
+19,776
| +54% | +$2.24M |
|
8
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.9B
| $6.45M | 2.74% |
90,000
+60,000
| +200% | +$4.23M |
|
9
PUT
Becton Dickinson
BDX
$46.4B
| $6.36M | 2.7% |
+38,438
| New | +$6.15M |
|
10
Bristol-Myers Squibb
BMY
$129B
| $6.34M | 2.7% |
86,250
+10,750
| +14% | +$760K |
|
|
SHPG
11
DELISTED
Shire pic
SHPG
| $5.52M | 2.35% |
30,000
+6,750
| +29% | +$1.22M |
|
12
Universal Health Services
UHS
$10.2B
| $5.36M | 2.28% |
40,000
-10,000
| -20% | -$1.32M |
|
|
EVHC
13
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $5.33M | 2.26% |
70,140
+11,690
| +20% | +$831K |
|
|
ALXN
14
DELISTED
Alexion Pharmaceuticals
ALXN
| $5.22M | 2.22% |
44,670
+8,670
| +24% | +$1.23M |
|
15
McKesson
MCK
$104B
| $5.13M | 2.18% |
27,500
+9,000
| +49% | +$1.58M |
|
|
16
Stryker
SYK
$135B
| $4.79M | 2.04% |
+40,000
| New | +$4.47M |
|
17
Eli Lilly
LLY
$1.08T
| $4.41M | 1.87% |
56,000
+14,000
| +33% | +$1.05M |
|
18
Insulet
PODD
$11.8B
| $4.4M | 1.87% |
145,500
-29,500
| -17% | -$918K |
|
|
ALXN
19
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
| $4.38M | 1.86% |
+37,500
| New | +$5.32M |
|
|
NXTM
20
DELISTED
NxStage Medical Inc.
NXTM
| $4.34M | 1.84% |
200,000
-40,157
| -17% | -$716K |
|
21
Boston Scientific
BSX
$68.4B
| $4.32M | 1.84% |
185,000
-115,000
| -38% | -$2.49M |
|
|
22
GSK
GSK
$107B
| $4.3M | 1.83% |
+79,300
| New | +$4.18M |
|
|
ACH
23
Accendra Health
ACH
$254M
| $4.16M | 1.77% |
111,400
+6,400
| +6% | +$241K |
|
24
Amgen
AMGN
$209B
| $4.15M | 1.76% |
27,250
+1,675
| +7% | +$260K |
|
|
25
Pfizer
PFE
$143B
| $4.14M | 1.76% |
124,029
-86,771
| -41% | -$2.77M |
|
Similar funds
GMP
BCA
ONGA
RC
CVV
DOFI
SRA
SR
Pura Vida Investments's Q2 2016 Portfolio in Review
As of Q2 2016, Pura Vida Investments held 99 positions worth $235M, up 7% from $220M the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Pura Vida Investments deployed $7.44M of net new capital in Q2 2016, opening 22 new positions and adding to 25 existing holdings. Its largest new stake was Medtronic: 80,000 shares worth $6.94M.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 60% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Allergan plc, an estimated $7.97M trimmed.
- Pura Vida Investments's largest Q2 2016 buy was Medtronic: 80,000 shares worth $6.94M.
- Pura Vida Investments added most to Centene in Q2 2016, an estimated $4.68M increase.
- Pura Vida Investments's biggest Q2 2016 reduction was Allergan plc, cutting an estimated $7.97M.
- Pura Vida Investments fully exited AbbVie in Q2 2016, selling an estimated $5.99M.
- Pura Vida Investments's ten largest holdings make up 31% of its $235M portfolio in Q2 2016.
- Pura Vida Investments opened 22 new positions and closed 25 in Q2 2016.
- Pura Vida Investments's portfolio value rose 7% quarter-over-quarter to $235M.
Based on Pura Vida Investments's 13F filing for Q2 2016, filed 15 Aug 2016.